Financials data is unavailable for this security.
View more
Year on year RaQualia Pharma Inc 's revenues fell -34.85% from 2.92bn to 1.90bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 723.39m to a loss of 323.66m.
Gross margin | 84.78% |
---|---|
Net profit margin | -29.28% |
Operating margin | -22.18% |
Return on assets | -7.77% |
---|---|
Return on equity | -11.08% |
Return on investment | -8.56% |
More ▼
Cash flow in JPYView more
In 2023, RaQualia Pharma Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 793.45m or 41.73% of revenues. In addition the company used 718.60m for operations while cash used for investing totalled 135.37m.
Cash flow per share | -18.95 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 261.02 |
---|---|
Tangible book value per share | 74.71 |
More ▼
Balance sheet in JPYView more
Current ratio | 3.69 |
---|---|
Quick ratio | 3.55 |
Total debt/total equity | 0.659 |
---|---|
Total debt/total capital | 0.3972 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items dropped -143.45%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -334.89 |